Is Salbutamol Safe During Pregnancy? What the Evidence Says
TL;DR
- Salbutamol (albuterol) is generally considered compatible with pregnancy and is classified as a preferred short-acting reliever for pregnant women with asthma by ACOG, NICE, and GINA guidelines.
- Uncontrolled asthma poses a greater risk to the mother and fetus than the use of inhaled salbutamol; poorly managed asthma is associated with pre-eclampsia, preterm birth, and low birth weight.
- A large European case-control study found modest statistical signals for cleft palate and gastroschisis with first-trimester inhaled β₂-agonist exposure, but these findings have not been confirmed as causal and must be weighed against the well-documented harms of untreated asthma.
Why Salbutamol Use in Pregnancy Matters
Asthma is the most common chronic respiratory disease to complicate pregnancy, affecting an estimated 4–8 % of pregnant women worldwide [VERIFY]. The natural course of asthma during pregnancy is unpredictable: roughly one-third of women improve, one-third worsen, and one-third remain stable [1]. When asthma deteriorates, the consequences can be serious for both the mother and the developing fetus. Poorly controlled asthma has been associated with pre-eclampsia, gestational diabetes, preterm delivery, intrauterine growth restriction, and low birth weight [1].
Salbutamol (Ventolin, ProAir, Proventil) is a selective β₂-adrenoceptor agonist and the most widely used short-acting bronchodilator in the world [8]. It works by relaxing airway smooth muscle, providing rapid relief of bronchospasm typically within minutes of inhalation [8]. For pregnant women with asthma, it serves as the first-line rescue medication recommended by every major guideline body, including the Global Initiative for Asthma (GINA), the American College of Obstetricians and Gynecologists (ACOG), the British Thoracic Society (BTS), and the National Institute for Health and Care Excellence (NICE) [VERIFY].
The central clinical principle is straightforward: the risk of uncontrolled asthma to the pregnancy substantially outweighs the risk of the medications used to control it [1]. This article examines the pharmacological evidence, safety data, guideline recommendations, and practical considerations for using salbutamol during pregnancy.
Pharmacology of Salbutamol Relevant to Pregnancy
Salbutamol is a short-acting β₂-agonist (SABA) with selectivity for β₂-adrenoceptors found in bronchial smooth muscle, uterine smooth muscle, and vascular beds [8]. When delivered via metered-dose inhaler (MDI) or nebulizer, systemic absorption is low—typically less than 10–20 % of the nominal dose reaches the systemic circulation via the lungs, while the majority of the swallowed fraction undergoes first-pass hepatic metabolism [VERIFY].
Key pharmacological properties relevant to pregnancy include:
Bronchodilation. The primary therapeutic effect. Onset occurs within 3–5 minutes of inhalation, with peak effect at 30–60 minutes and duration of action of 4–6 hours [8]. This rapid onset makes salbutamol essential for acute symptom relief.
Uterine relaxation (tocolysis). β₂-agonists relax uterine smooth muscle, which is why salbutamol and related agents (ritodrine, terbutaline, fenoterol) have historically been used as tocolytics to inhibit preterm labor [2]. However, the doses required for tocolysis are substantially higher than those used in inhaled asthma therapy—typically intravenous infusions rather than metered-dose puffs.
Cardiovascular effects. At standard inhaled doses (100–200 µg per actuation, 1–2 puffs), salbutamol does not produce clinically meaningful changes in heart rate [7]. Only at doses 5–10 times the standard nebulized dose of 2.5 mg does a 20–30 beat-per-minute increase in heart rate become apparent [7]. Importantly, the incidence of arrhythmias with salbutamol at standard doses is comparable to placebo [7].
Metabolic effects. Systemic β₂-agonist exposure can cause transient hypokalemia, hyperglycemia, and tremor, but these effects are dose-dependent and generally negligible at standard inhaled doses [8].
The distinction between inhaled and systemic routes is critical in pregnancy. Inhaled salbutamol delivers microgram-level doses directly to the airways, minimizing fetal exposure. Intravenous or high-dose nebulized salbutamol, as used in tocolysis or severe asthma exacerbations, produces systemic drug levels that are orders of magnitude higher and carry a different risk profile.
Salbutamol Safety Data in Pregnancy: What the Studies Show
Observational and registry data
The largest body of evidence on salbutamol safety during pregnancy comes from observational studies and congenital anomaly registries. A pivotal European case-malformed control study by Garne and colleagues analyzed data from 76,249 registrations of congenital anomalies across 13 EUROmediCAT registries [6]. The investigators tested signals previously identified in the literature regarding first-trimester exposure to inhaled β₂-agonists.
The study found statistically significant associations between first-trimester use of inhaled β₂-agonists and two specific anomalies [6]:
- Cleft palate — OR 1.63 (95 % CI: 1.05–2.52)
- Gastroschisis — OR 1.89 (95 % CI: 1.12–3.20)
Odds of exposure to salbutamol specifically were similar to the class-level results [6]. Importantly, the study found no significant associations with spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot [6]. Similarly, none of the four literature-derived signals for inhaled corticosteroids (cleft palate, cleft lip, anal atresia, hypospadias) were confirmed [6].
Interpreting the signals
These findings require careful interpretation. The absolute risk increase, even if the association is causal, is small. The baseline prevalence of cleft palate is approximately 1 in 1,500–2,500 live births [VERIFY], meaning an odds ratio of 1.63 would translate into a very modest increase in absolute terms. Furthermore, observational studies cannot fully account for confounding by indication—women taking inhaled β₂-agonists have asthma, and asthma itself (or its severity, or co-exposures including cigarette smoke) may contribute to the observed associations.
The study authors themselves noted that these signals need further investigation and should not deter women from using necessary asthma medications [6]. Every major guideline body has reviewed this evidence and continues to recommend salbutamol as a preferred reliever during pregnancy.
Tocolytic use data
When salbutamol is used at higher, systemic doses for tocolysis (suppression of preterm labor), the safety profile differs. A comprehensive review of tocolytic safety noted that maternal safety concerns have reduced the use of β₂-agonists as tocolytics [2]. The main concerns with systemic β₂-agonist tocolysis include maternal tachycardia, palpitations, tremor, hypokalemia, hyperglycemia, and rare but serious pulmonary edema [2]. For this reason, first-line tocolytic therapy in Europe has shifted to calcium channel blockers (nifedipine) and oxytocin receptor antagonists (atosiban), with β₂-agonists now used less frequently [2].
It is essential to distinguish these systemic tocolytic doses from standard inhaled doses. The risks identified with tocolytic use do not extrapolate to standard inhaled salbutamol therapy for asthma.
Salbutamol Dosing in Pregnancy: Inhaled vs. Systemic Routes
| Parameter | Inhaled (MDI/nebulizer) for asthma | IV/SC for tocolysis | SC before ECV |
|---|---|---|---|
| Typical dose | 100–200 µg per puff (MDI); 2.5–5 mg nebulized | 10–45 µg/min IV infusion | 0.5 mg SC single dose [3] |
| Systemic exposure | Low (< 20 % of dose) | High (direct systemic) | Moderate (systemic absorption) |
| Duration of use | Intermittent, as-needed | Hours to days | Single pre-procedure dose |
| Primary guideline position | First-line reliever; preferred in pregnancy (GINA, ACOG, NICE) | Second-line tocolytic; declining use [2] | Used as uterine relaxant prior to ECV [3] |
| Key maternal concerns | Tremor, palpitations (rare at standard dose) | Tachycardia, hypokalemia, pulmonary edema [2] | Tachycardia, tremor |
| Fetal concerns | No confirmed teratogenic effect at standard doses [6] | Fetal tachycardia, neonatal hypoglycemia | Transient fetal tachycardia |
A study comparing subcutaneous salbutamol to intramuscular ritodrine prior to external cephalic version (ECV) found that both agents were effective at relaxing the uterus to facilitate the procedure, though success rates were higher in the ritodrine group (71.7 % vs. 63.8 %, p = 0.003) [3]. This demonstrates another clinical context in which salbutamol is administered systemically during pregnancy, albeit as a single dose.
Adverse Effects and Safety Profile of Salbutamol in Pregnancy
| Adverse effect | Frequency at inhaled doses | Recommended action |
|---|---|---|
| Tremor (hands) | Common (≈ 10–20 %) | Usually mild and self-limiting; reassure patient |
| Palpitations / tachycardia | Occasional (1–10 %) | Monitor; usually resolves. No clinically significant arrhythmias at standard doses [7] |
| Headache | Occasional (1–10 %) | Symptomatic management |
| Hypokalemia | Rare at inhaled doses; more common with nebulized/IV | Monitor potassium if using high or repeated doses |
| Hyperglycemia | Rare at inhaled doses | Relevant if gestational diabetes present; monitor glucose |
| Muscle cramps | Occasional | Reassure; usually transient |
| Pulmonary edema | Extremely rare; associated with IV tocolytic use [2] | Stop infusion immediately; emergency management |
| Neonatal hypoglycemia | Reported after systemic tocolytic use | Monitor neonatal blood glucose after delivery |
| Fetal tachycardia | Possible with systemic dosing; unlikely with inhaled | Monitor fetal heart rate if concern arises |
Red flags requiring immediate medical attention:
- Chest pain or sustained palpitations unresponsive to stopping the inhaler
- Dyspnea worsening despite salbutamol use (may indicate severe exacerbation requiring emergency care)
- Reduced fetal movements following high-dose nebulized treatment
- Signs of pulmonary edema (acute shortness of breath, frothy sputum, hypoxia) during IV tocolysis
Recent evidence from a 2025 review confirmed that salbutamol at standard dosages does not significantly affect heart rate in diverse patient populations—including emergency department and ICU patients—and does not induce severe arrhythmias even in arrhythmia-prone populations [7]. This provides additional reassurance for pregnant women concerned about cardiac safety.
Clinical Pearls and Special Populations
Stepping up therapy in pregnancy
Salbutamol should remain the rescue inhaler throughout pregnancy, but its frequent use (more than 2 days per week for symptom relief, or using more than one canister per month) signals inadequate asthma control and the need to step up controller therapy [1]. Inhaled corticosteroids (ICS), particularly budesonide, are the preferred controller medications in pregnancy based on the largest body of safety data [1] [4]. A multidisciplinary approach involving obstetricians, asthma specialists, and pediatricians is recommended to optimize the management plan for each patient [1].
Allergic rhinitis co-management
Many pregnant women with asthma also have allergic rhinitis, which can exacerbate lower airway inflammation. Research into the immunomodulatory effects of salbutamol has shown it can modulate Th2 cytokine expression pathways involved in allergic inflammation [4]. While salbutamol is noted as generally usable during pregnancy and breastfeeding, it is not a first-line treatment for allergic rhinitis; intranasal corticosteroids remain preferred for nasal symptoms [4].
COPA syndrome and rare autoimmune conditions
In rare autoimmune conditions complicating pregnancy, such as COPA syndrome, salbutamol (as albuterol) has been used as a bronchodilator alongside inhaled corticosteroids under specialist supervision [5]. This case illustrates the broader principle that salbutamol remains a cornerstone of bronchospasm management regardless of the underlying etiology, and that its safety in pregnancy makes it a practical choice even in complex clinical scenarios [5]. Preconception counseling is recommended to ensure that all medications are pregnancy-compatible [5].
Breastfeeding considerations
Salbutamol is considered compatible with breastfeeding by the AAP and the UK Drugs in Lactation Advisory Service (UKDILAS) [VERIFY]. Inhaled salbutamol produces very low plasma levels, and the amount excreted into breast milk is considered negligible and not expected to affect the nursing infant [4].
Gestational diabetes
Pregnant women with gestational diabetes using salbutamol should be aware that systemic β₂-agonist exposure can transiently raise blood glucose levels. At standard inhaled doses, this effect is generally clinically insignificant. However, during acute exacerbations requiring repeated nebulized doses, glucose monitoring may be warranted [VERIFY].
Pre-eclampsia and hypertensive disorders
There is no established contraindication to inhaled salbutamol in women with pre-eclampsia or gestational hypertension. At standard inhaled doses, the vasodilatory and cardiac effects are minimal [7]. If anything, the β₂-mediated vasodilation may theoretically be modestly beneficial, though this is not a therapeutic indication.
FAQ
Q1: Can I use my salbutamol inhaler in the first trimester? A1: Yes. All major guidelines, including GINA and ACOG, recommend continuing salbutamol as a rescue inhaler throughout pregnancy, including the first trimester. While one large European study identified modest statistical associations between first-trimester inhaled β₂-agonist use and cleft palate (OR 1.63) and gastroschisis (OR 1.89), these findings do not establish causation and the absolute risk increase is very small [6]. The risks of uncontrolled asthma to both mother and baby are well-documented and far exceed these uncertain signals [1].
Q2: Is nebulized salbutamol safe during pregnancy? A2: Nebulized salbutamol (typically 2.5–5 mg) is used for moderate-to-severe asthma exacerbations and is considered appropriate during pregnancy when clinically indicated. The dose is higher than from an MDI, so systemic absorption is greater. Transient maternal tachycardia and tremor may occur. For severe exacerbations, withholding treatment poses a far greater threat—maternal hypoxia can lead to fetal hypoxia and adverse outcomes [1]. Hospital-based monitoring of maternal vital signs and fetal heart rate is advisable during nebulized treatment.
Q3: Will salbutamol affect my baby's heart rate? A3: At standard inhaled doses, salbutamol is unlikely to cause fetal tachycardia. A 2025 review confirmed that standard-dose salbutamol does not significantly alter heart rate even in adult populations, and the systemic levels achieved with inhaled use are very low [7]. Fetal tachycardia is more of a concern with systemic (IV or high-dose nebulized) administration, such as during tocolysis.
Q4: I have been using salbutamol more than 3 times per week. Should I be worried? A4: Frequent salbutamol use (more than twice per week for symptom relief) is an indicator of poorly controlled asthma rather than a direct safety concern from the drug itself [1]. You should speak with your healthcare provider about stepping up your controller therapy—typically an inhaled corticosteroid such as budesonide, which has a strong pregnancy safety profile [1] [4]. Better asthma control means better outcomes for both you and your baby.
Q5: Can salbutamol cause preterm labor or stop contractions? A5: Salbutamol relaxes uterine smooth muscle, which is why it has historically been used as a tocolytic to delay preterm labor [2]. At standard inhaled asthma doses, the systemic levels are far too low to produce meaningful uterine relaxation. There is no evidence that using a salbutamol inhaler for asthma increases or decreases the risk of preterm labor. When used as a tocolytic (intravenously), it can delay delivery by 48 hours—enough time to administer antenatal corticosteroids—but it is no longer first-line for this indication due to maternal side effects [2].
References
[1] Maselli DJ, Adams SG, Peters JI. Therapeutic Advances in Respiratory Disease 2013. PMID: 23129568. pubmed.ncbi.nlm.nih.gov/23129568
[2] Lamont RF, Jørgensen JS. Current Pharmaceutical Design 2019. PMID: 30931850. pubmed.ncbi.nlm.nih.gov/30931850
[3] Levin G, Cahan T, Weill Y. Minerva Obstetrics and Gynecology 2022. PMID: 35107244. pubmed.ncbi.nlm.nih.gov/35107244
[4] Ma Y, Yang XH, Tu Y. Fundamental & Clinical Pharmacology 2023. PMID: 36314138. pubmed.ncbi.nlm.nih.gov/36314138
[5] Ayyar A, Seaman RD, Guntupalli K. Case Reports in Obstetrics and Gynecology 2022. PMID: 35284147. pubmed.ncbi.nlm.nih.gov/35284147
[6] Garne E, Hansen AV, Morris J. The Journal of Allergy and Clinical Immunology 2015. PMID: 26220526. pubmed.ncbi.nlm.nih.gov/26220526
[7] Lucassen EA, Rood R, Tibboel J. Nederlands Tijdschrift voor Geneeskunde 2025. PMID: 40673353. pubmed.ncbi.nlm.nih.gov/40673353
[8] Price AH, Clissold SP. Drugs 1989. PMID: 2670512. pubmed.ncbi.nlm.nih.gov/2670512
About the author
Dr. Stanislav Ozarchuk, PharmD, has 15 years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.
Medical disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.